Plasma IGFBP-2 levels after postoperative combined radiotherapy and chemotherapy predict prognosis in elderly glioblastoma patients

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Han, Sheng ^a   Meng, Lingxuan ^a   Han, Shuai ^a   Wang, Yunjie ^a   Wu, Anhua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; SOMATOMEDIN BINDING PROTEIN 2; IGFBP-2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CLINICAL FEATURE; CONTROLLED STUDY; ELDERLY CARE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POSTOPERATIVE CARE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; BLOOD; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; POSTOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898670855     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093791     Document Type: Article

References (31)

1. Quaranta M, Divella R, Daniele A, Di TS, Venneri MT, et al. (2007) Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. Tumori 93: 275-280. (Pubitemid 47080014)
2. Malkoun N, Chargari C, Forest F, Fotso MJ, Cartier L, et al. (2012) Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol 106: 127-133.
3. Natsume A, Kato T, Kinjo S, Enomoto A, Toda H, et al. (2012) Girdin maintains the stemness of glioblastoma stem cells. Oncogene 31: 2715-2724.
4. Iliadis G, Kotoula V, Chatzisotiriou A, Televantou D, Eleftheraki AG, et al. (2012) Volumetric and MGMT parameters in glioblastoma patients: survival analysis. BMC Cancer 12: 3.
5. Duarte CW, Willey CD, Zhi D, Cui X, Harris JJ, et al. (2012) Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS One 7: e29653.
6. Wang Y, Li S, Chen L, You G, Bao Z, et al. (2012) Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol 14: 518-525.
7. Carico C, Nuno M, Mukherjee D, Elramsisy A, Dantis J, et al. (2012) Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS One 7: e33684.
8. Lin Y, Jiang T, Zhou K, Xu L, Chen B, et al. (2009) Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol 11: 468-476.
9. Zhang J, Huang K, Shi Z, Zou J, Wang Y, et al. (2011) High beta-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression. Neuro Oncol 13: 600-609.
10. Han S, Xia J, Qin X, Han S, Wu A (2013) Phosphorylated SATB1 is associated with the progression and prognosis of glioma. Cell Death Dis 4: e901.
11. Han S, Tie X, Meng L, Wang Y, Wu A (2013) PMA and ionomycin induce glioblastoma cell death: activation-induced cell-death-like phenomena occur in glioma cells. PLoS One 8: e76717.
12. Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T (2012) Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro Oncol 14: 109-116.
13. Zhang W, Wang H, Song SW, Fuller GN (2002) Insulin-like growth factor binding protein 2: gene expression microarrays and the hypothesis-generation paradigm. Brain Pathol 12: 87-94. (Pubitemid 33131365)
14. Zhou YH, Hess KR, Liu L, Linskey ME, Yung WK (2005) Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables. Neuro Oncol 7: 485-494. (Pubitemid 41555620)
15. Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, et al. (2001) Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter. Cancer Res 61: 8601-8610. (Pubitemid 34013863)
16. van den Beld AW, Blum WF, Pols HA, Grobbee DE, Lamberts SW (2003) Serum insulin-like growth factor binding protein-2 levels as an indicator of functional ability in elderly men. Eur J Endocrinol 148: 627-634. (Pubitemid 36758292)
17. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
18. Clemmons DR (2007) Value of insulin-like growth factor system markers in the assessment of growth hormone status. Endocrinol Metab Clin North Am 36: 109-129. (Pubitemid 46335846)
19. Chakrabarty S, Kondratick L (2006) Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells. Cancer Biol Ther 5: 189-197. (Pubitemid 43328877)
20. Chatterjee S, Park ES, Soloff MS (2004) Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2. Int J Urol 11: 876-884. (Pubitemid 39490739)
21. Azar WJ, Zivkovic S, Werther GA, Russo VC (2013) IGFBP-2 nuclear translocation is mediated by a functional NLS sequence and is essential for its pro-tumorigenic actions in cancer cells. Oncogene. 33:578-588.
22. Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, et al. (2006) High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer 16: 1529-1535. (Pubitemid 44060375)
23. Santosh V, Arivazhagan A, Sreekanthreddy P, Srinivasan H, Thota B, et al. (2010) Grade-specific expression of insulin-like growth factor-binding proteins-2,-3, and-5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma. Cancer Epidemiol Biomarkers Prev 19: 1399-1408.
24. Kulkarni A, Thota B, Srividya MR, Thennarasu K, Arivazhagan A, et al. (2012) Expression pattern and prognostic significance of IGFBP isoforms in anaplastic astrocytoma. Pathol Oncol Res 18: 961-967.
25. Hu D, Pawlikowska L, Kanaya A, Hsueh WC, Colbert L, et al. (2009) Serum insulin-like growth factor-1 binding proteins 1 and 2 and mortality in older adults: the Health, Aging, and Body Composition Study. J Am Geriatr Soc 57: 1213-1218.
26. Foulstone EJ, Zeng L, Perks CM, Holly JM (2013) Insulin-Like Growth Factor Binding Protein 2 (IGFBP-2) Promotes Growth and Survival of Breast Epithelial Cells: Novel Regulation of the Estrogen Receptor. Endocrinology 154: 1780-1793.
27. Russo VC, Schutt BS, Andaloro E, Ymer SI, Hoeflich A, et al. (2005) Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology 146: 4445-4455. (Pubitemid 41324043)
28. Hoeflich A, Fettscher O, Preta G, Lahm H, Kolb HJ, et al. (2003) Increased activity of catalase in tumor cells overexpressing IGFBP-2. Horm Metab Res 35: 816-821. (Pubitemid 38058188)
29. Kitszel A, Krawczuk-Rybak M (2007) Are elevated serum levels of IGFBP-2 after intensive chemotherapy of childhood acute lymphoblastic leukemia a risk factor of relapse. Adv Med Sci 52: 147-153.
30. Mattsson A, Svensson D, Schuett B, Osterziel KJ, Ranke MB (2008) Multidimensional reference regions for IGF-I, IGFBP-2 and IGFBP-3 concentrations in serum of healthy adults. Growth Horm IGF Res 18: 506-516.
31. Amin S, Riggs BL, Melton LJ 3rd, Achenbach SJ, Atkinson EJ, Khosla S (2007) High serum IGFBP-2 is predictive of increased bone turnover in aging men and women. J Bone Miner Res 22: 799-807. (Pubitemid 351339739)